Member Info for bald_eagle

Never heard of 'Master Investor' myself, the phrase "more growth and cash than you can shake a stick at" doesn't seem a very professional way of describing a company with high growth and strong cash position...but I suppose it depends on their target audience.
Financial journalists who used such language I imagine to be about 15 years old....most of the Motley Fool staff for example.

You ladies aren't buying enough, come on!!! get busy with your ISA's....or perhaps you really like me & don't want me to go.

It's nice to be wanted...as the convict said to the policewoman!!

"lets hope for everyone's sake it peters out and dies...."
======================
There isn't any evidence that the virus will 'peter out and die'....no person of science has suggested that it will disappear (none I have encountered). Probably the best will be that the virus can be suppressed once lockdown is eased and cases can be kept at low levels...until the vaccination is available next year....or some sort of herd immunity happens.

"back to 20p first stop"
========================
Got to get to 13p first!!!

"Hopefully we will get to that 13p today for some sensible peace after that"
=====================
I'll second that!!

For clarity: "Each DermaSys® formulation is separately patented..."

Probably means nothing but they seem to have dropped the 'patent' from their description of DermaSys, which is now "...proprietary, transdermal DermaSys® technology"

The 2nd FDA meeting will be crucial: "....to further discuss clinical sufficiency and/or post-marketing requirements once the clinical study report ("CSR") for FM57 is available"

A rather stupid question but I feel I have to ask it..."Why are carnival still having cruises in the middle of a pandemic?"

It's crazy, it's illogical...is it the sign of a management who have lost the plot???

'heated, cooling cycle the enervated the nerves in the c0ck'.

typo and 'why is p3nis' a dirty word?

FrankMu, thank you for your response.

If FUM are indeed applying for a patented formulation (possibly a molecule) it doesn't quite agree with the way Ken James described how MED3000 is thought to work, some sort of 'heated, cooling cyscle the enervated the nerves in the *****'....which to a layman would be a mode of action (or a physical process). Since MED3000 is based on a placebo derived formulation it rather begs the question.."what is the active ingredient?"....what is the 'molecule' that is being delivered through the skin barrier by DermaSys?

You do also suggest that the examiner might "ask for more clarification about the mechanisms of action though."...surely that is the mode of action. Which brings us back to the basic question...is MED3000 a physical or a chemical phenomenon?

snap!!

https://www.bbc.co.uk/news/world-australia-52171181

LuckyL, Carnival or a derivation will always exist. The risky thing for shareholders is that the structure of the company may be totally different. Like in some UK care homes....the businesses were refinanced, selling off the buildings (or ships in this case) to third party companies (presumably some sort of hedge fund) who charged extortionate rents. The care homes struggled to meet the rents....a recipe for disaster. Same with some smaller football clubs, who sold off the grounds (about their only asset)....sounded like a good idea, until they hit a sticky financial spot & they don't have an assets. The club disappears...the smart money sells the ground for houses.

CCL have to try to weather the storm (next 18-24 months) and try to keep the sharks at bay.

theItalian, didn't mean to imply that PE is the same or even similar to ED. Just filling in the gap on the FUM product that I couldn't remember. Please ignore because PET500 is irrelevant to FUM's future...although it is part of the history of course.

Your point on Fortacin is interesting. Sometimes despite the best hopes of 'management' a product just doesn't take off in a region. Whether that is people prefer to stick with what they know, cultural reasons, or simply a lack of marketing budget.

CSD500 was delayed & delayed & delayed....some delay in regulatory approval, then pharma partners messing them about...then the 2 year shelf life fiasco (self inflicted & entirelt FUM's fault IMO)...when it was finally ready it had to battle generic viagra. Perhaps if it was released earlier it would have got some traction...who knows, water under the bridge. But still part of FUM's history of course.

PET500 is a topical spray that combines our highly efficient DermaSys® AquaFree delivery system with a well-known mild topical anaesthetic. PET500 is licensed to Ansell, one of the world's major sexual health companies, who have worldwide rights to the product and who launched the product in the USA under the name EPIC®. The product is designed to take effect rapidly and to delay male ejaculation, thereby offering enhanced sexual control. Whilst EPIC® was made available in stores throughout the USA, its sales have been modest to the extent that it is no longer stocked by a major US retailer. We believe that the sales performance reflects a lack of promotional activity and we continue to explore how to take the product forwards. [interim results, sept 2015]

I believe that is the last mention of PET500.

"PET500, our innovative spray for enhanced sexual control, which is licensed to Ansell Limited, is progressing through its phased launch and roll out in the USA." [interim results, sept 2012]

I think PET500 was for premature ejaculation...released in Walgreens but soon disappeared.

theItalian, your opinion is as valid as anyone elses and appreciated. Patents are complicated (from the little I know) and it is unlikely many of us (apart from FrankMu of course) have an opinion that isn't biased to some extent. As long as people are aware of some of the more obvious risks.

As I say, I don't know enough about requirements for getting a patent. Fum have got patents for Dermasys before but MED3000 may be different. The mode of action for MED3000 (placebo derived) seems to be somewhat unique. I suppose it depends on the patent application and what feature they are patenting. Based on what Ken James has said the BOD have a theory on how MED3000 works and they are presumably working on verifying that. The patent office will decide if that can be patented.

I'm not sure how much weight potential distribution partners will place on whether MED3000 is patented. Perhaps they are more interested in regulatory approval. Ultimately if FUM do get a product on the shelf then it will be customer demand driven by efficacy of the product that will generate revenues. But I'm not sure pharma companies will see MED3000 as a wonder product demanding a high upfront payment....possibly they will based any deal on sales. Which could mean a rights issue h1 2021 becomes unavoidable.

Several of FUM's products have failed to create a stir with customers...CSD500 the obvious one and there was another (which eludes me). Hopefully MED3000 can actually deliver on the expectations/excitement of 'the management' this time.

Trump had a meeting with US oil producers...presumably to ask them to cut production too. They seem to have told him where to go. Trump has now changed his tune by leaving oil price to 'market forces'.

Very interesting programme on Aljazeera: "Is the oil price war between Saudi Arabia and Russia ending?"

https://www.aljazeera.com/programmes/insidestory/2020/04/oil-price-war-saudi-arabia-russia-200403194255695.html

"... the company will then struggle to survive. "
========================================
Raleigh, from the current look of things a lot of companies will struggle to survive. Some indeed will go to the wall, to be replaced by other entities to provide the service (assuming that there is still demand). Others will use the downtime to prepare for the future and emerge stronger. That's when one really finds out the quality of the management. Headless chickens or visionary leaders!!
I'm not sure where CCL fits in to the above scenario.
Personally I would split the board into two groups...one to cut costs, whilst supporting the workforce. The second preparing for the future e.g. making CCL best in class for cleanliness & virus handling protocols, preparing the fleet for a low carbon future, staff training etc etc.
The aim should be to weather the financial storms ahead and hit the ground running when a vaccine is available.